Basic and Clinical Aspects of Lymphoma

January 10-14, 1997
Renaissance Esmeralda Resort
Indian Wells (Palm Springs), CA

Supported by a Generous Educational Grant from the Cure For Lymphoma Foundation
(Corporate Support to be Listed in Future Announcements)

CONFERENCE CO-CHAIRPERSONS
Joseph R. Bertino / New York, NY  James O. Armitage / Omaha, NE

HONORARY CHAIRPERSON
Saul A. Rosenberg / Stanford, CA

PROGRAM COMMITTEE
Franco G. Cavalli / Bellinzona, Switzerland  Bruce A. Chabner / Boston, MA
Raju S. K. Chaganti / New York, NY  Richard I. Fisher / Maywood, IL
Thomas M. Grogan / Tucson, AZ  Alexandra M. Levine / Los Angeles, CA
Ronald Levy / Stanford, CA  Sharon B. Murphy / Chicago, IL

CONFERENCE PROGRAM

Keynote Address
Saul A. Rosenberg / Stanford, CA

The New Entities and Classification
Nancy L. Harris / Boston, MA
Dennis D. Weisenburger / Omaha, NE
James O. Armitage / Omaha, NE
Richard I. Fisher / Maywood, IL

Lymphomagenesis and Etiology
Franco G. Cavalli / Bellinzona, Switzerland
Richard F. Ambinder / Baltimore, MD

Lymphoma Associated with
Immunodeficiency
Daniel Knowles / New York, NY
Lode J. Swinnen / Maywood, IL
Alexandra M. Levine / Los Angeles, CA

Genetic Abnormalities in Lymphoma
Raju S. K. Chaganti / New York, NY
Riccardo Dalla-Favera / New York, NY
Stephan W. Morris / Memphis, TN
Diane C. Louie / New York, NY

Cell Adhesion and Cell Signaling/
Molecular and Homing Receptors
Thomas M. Grogan / Tucson, AZ
Douglas R. Green / San Diego, CA

Can We Improve Outcome with Available Therapies?
Sharon B. Murphy / Chicago, IL
Joseph R. Bertino / New York, NY
John H. Glick / Philadelphia, PA

New Therapies
Bruce A. Chabner / Boston, MA
Oliver W. Press / Seattle, WA
Ronald Levy / Stanford, CA
Richard J. O'Reilly / New York, NY
Finbarr E. Cotter / London, England

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for oral and poster presentation.

Application Deadline: November 25, 1996

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300  215-440-9313 (FAX)
World Wide Web: http://www.aacr.org
Michael M. Gottesman, featured on the cover, joined the permanent staff of the National Cancer Institute (NCI) in 1976. He became Chief of the Molecular Cell Genetics Section of the Laboratory of Molecular Biology in 1980 and Chief of the Laboratory of Cell Biology in 1990, and he was Acting Director for the National Center for Human Genome Research (NCHGR) from 1992 to 1993 and also Acting Scientific Director of the NCHGR from April 1993 to October 1993. He has been Deputy Director for Intramural Research at the National Institutes of Health (NIH) since November 1993. At the NIH, his research interests have ranged from how DNA is replicated in bacteria to how cancer cells elude chemotherapy, and he has published extensively on these subjects. He helped establish the fledgling field of molecular cell genetics by isolating and characterizing mutants of CHO cells resistant to cAMP due to defects in cAMP-dependent protein kinase (Somatic Cell Genet., 6: 45, 1980). He also isolated mutants resistant to antimicrotubule agents due to altered tubulins, providing the first genetic demonstration that tubulin was essential for mitotic spindle formation in mammalian cells (Cell, 20: 29, 1980). During the past 10 years, in close collaboration with Ira Pastan, he has identified the human gene (MDR1) responsible for the resistance of cancer cells to many of the most common anticancer drugs (Science, 232: 643, 1986; Cell, 47: 381, 1986), and he has shown that this gene encodes a protein that acts to pump anticancer drugs out of many drug-resistant human cancers (Cancer Res., 53: 747, 1993).

His current work in the Laboratory of Cell Biology is directed toward understanding the mechanism by which this multidrug transporter works. These studies will have implications for the design of strategies to circumvent drug resistance in cancer. In addition, his laboratory is interested in the development of vectors for gene therapy in which the multidrug resistance gene serves as a dominant selectable marker for protection of bone marrow during chemotherapy and as a means to introduce other nonselectable genes into bone marrow and other tissues sensitive to cytotoxic anticancer drugs. Dr. Gottesman’s work on multidrug resistance has been recognized by several awards, including the Milken Family Foundation Cancer Research Award (1990) and the Richard and Hinda Rosenthal Foundation Award (1992), which is presented each year at the American Association for Cancer Research (AACR) annual meeting.

As Deputy Director for Intramural Research at the NIH, Dr. Gottesman has sought to improve the research environment at the NIH through support of a rigorous review process for intramural science and scientists, development of transinstitute special interest groups and seminar series, and reduction of administrative impediments to research. During his NIH career, he initiated several training and mentoring programs for high school students and teachers, as well as college and graduate students. To improve the diversity of the intramural scientific staff, he has instituted training programs to provide opportunities for minority and disadvantaged students and loan repayment programs for clinical researchers at the NIH.

Dr. Gottesman’s professional activities include membership in the AACR, the American Society for Biochemistry and Molecular Biology, and the American Society for Cell Biology. His service to the AACR includes his election to the Board of Directors in 1995 and his dedicated chairmanship of the Science Education Committee since 1991. He is also a member of the Minority Issues Committee (1992–) and has served on the Publications Committee (1993–96) and the Program Committee (1990 and 1991), acting as Chairperson for the Experimental Therapeutics and Preclinical Pharmacology Subcommittee in 1991.

In addition to serving as an Associate Editor for the AACR journals Cancer Research and Cell Growth & Differentiation, he has also been on the Editorial Boards of several other periodicals, including Journal of Cell Biology, Journal of Biological Chemistry, Cellular Physiology and Biochemistry, Molecular Pharmacology, Molecular Biology of the Cell, Journal of the National Cancer Institute, Seminars in Cancer Biology, Human Gene Therapy, and GenoMethods. Furthermore, he edited three books on molecular cell genetics. He is the recipient of the James Tolbert Shipley Prize and the Soma Weiss Award (Harvard Medical School), and he was also a Fellow of the American Association for the Advancement of Science in 1988. In 1991, he received the C. E. Ailen Prize, the Samuel G. Taylor III Award for Excellence in Cancer Research, and the Jefferson Cancer Institute Prize. He presented an NIH Award Lecture in January 1992, received the NCHGR Leadership Award in March 1994, and was awarded the Public Health Service Commendation Award in 1994 and the Public Health Outstanding Service Medal in 1995.

Dr. Gottesman was born on October 7, 1946, in Jersey City, NJ, and grew up in Flushing, NY. He attended Harvard College, where he graduated summa cum laude in Biochemical Sciences in 1966 and was married the same year to Susan Kemelhor. He received his M.D. from Harvard Medical School in 1970 and completed a medical internship and residency at the Peter Bent Brigham Hospital in Boston. His research training began at Harvard in the laboratories of William S. Beck and Bert L. Vallee and continued in the laboratory of Martin Gellert at the NIH as a Research Associate from 1971 to 1974. Dr. Gottesman spent a year as an Assistant Professor at Harvard Medical School and then, together with his wife Susan, who is a bacterial geneticist, moved on to the NCI. An excellent overview of Dr. Gottesman’s work is provided in his Rosenthal Lecture, which was published in Cancer Research (53: 747, 1993).